Treatment of pigs with PCV2 antigen
The present invention relates to a method for the treatment or prophylaxis of a PCV2 infection or for reduction of clinical symptoms caused by or associated with a PCV2 infection in animals a) having anti-PCV2 antibodies and/or b) being young piglets of 1 to 22 days of age, comprising the step of administering an effective amount of a PCV2 antigen to that animal in need of such treatment. Preferably, those animals are pigs or young piglets.
1. A method for the treatment of
a) PCV2 infection; or
b) clinical symptoms caused by or associated with a PCV2 infection in piglets having anti-PCV2 antibodies, comprising the step of administering a single dose of an immunogenic composition comprising a PCV2 ORF2 antigen and a veterinary-acceptable carrier to a piglet, wherein the single dose induces an immune response against PCV2 in the piglet.
2. The method according to claim 1 , wherein said anti-PCV2 antibodies are maternal antibodies.
3. The method according to claim 1 , wherein said treatment of PCV2 infection results in an improvement in comparison to animals of a non-treated control group of the same species in a vaccine efficacy parameter selected from the group consisting of a reduction in the loss of weight gain, a shorter duration of viremia, a reduction in viral excretion, a lower virus load, and any combination thereof.
4. The method according to claim 1 , wherein the anti-PCV2 antibodies are present in an antibody titer of at least 1:100-1:320 as determined in a PCV-specific indirect immunofluorescence assay.
5. The method according to claim 4 , wherein the treated animals have said anti-PCV2 antibody titre at the time the PCV2 antigen is administered.
6. The method of claim 1 , wherein the veterinary-acceptable carrier is an adjuvant.
7. The method of claim 1 , wherein the immunogenic composition further comprises gentamicin and/or merthiolate.
8. The method of claim 1 , wherein the immune response against PCV2 results in increased PCV2 serological titers two months after administration compared to a non-treated control group.
9. The method of claim 1 , wherein the immune response to PCV2 is a protective immunological response.
10. The method according to claim 1 , wherein the treatment results in a reduction in lymphoid infection by PCV2 as determined by immunohistochemistry.
11. A method for the treatment of
a) PCV2 infection; or
b) clinical symptoms caused by or associated with a PCV2 infection in piglets having anti-PCV2 antibodies, comprising the step of administering a single dose of an immunogenic composition comprising a PCV2 ORF2 antigen and a veterinary-acceptable carrier to a piglet, wherein the administration of the single dose is effective for the vaccination of a piglet 3 weeks of age or older against PCV2 infection.
12. The method according to claim 11 , wherein said anti-PCV2 antibodies are maternal antibodies.
13. The method according to claim 11 , wherein said treatment of PCV2 infection results in an improvement in comparison to animals of a non-treated control group of the same species in a vaccine efficacy parameter selected from the group consisting of a reduction in the loss of weight gain, a shorter duration of viremia, a reduction in viral excretion, a lower virus load, and any combination thereof.
14. The method according to claim 11 , wherein the anti-PCV2 antibodies are present in an antibody titer of at least 1:100-1:320 as determined in a PCV-specific indirect immunofluorescence assay.
15. The method according to claim 14 , wherein the treated animals have said anti-PCV2 antibody titre at the time the PCV2 antigen is administered.
16. The method of claim 11 , wherein the veterinary-acceptable carrier is an adjuvant.
17. The method of claim 11 , wherein the immunogenic composition further comprises gentamicin and/or merthiolate.
18. The method of claim 11 , wherein the vaccination results in an immune response against PCV2 that includes increased PCV2 serological titers two months after administration compared to a non-treated control group.
19. The method of claim 18 , wherein the immune response to PCV2 is a protective immunological response.
20. The method according to claim 11 , wherein the treatment results in a reduction in lymphoid infection by PCV2 as determined by immunohistochemistry.
21. A method for the treatment of
a) PCV2 infection; or
b) clinical symptoms caused by or associated with a PCV2 infection in piglets having anti-PCV2 antibodies, comprising the step of administering a single dose of an immunogenic composition comprising a PCV2 ORF2 antigen and gentamicin and/or merthiolate to a piglet and, wherein the single dose induces an immune response against PCV2 in the piglet.
22. The method according to claim 21 , wherein said anti-PCV2 antibodies are maternal antibodies.
23. The method according to claim 21 , wherein said treatment of PCV2 infection results in an improvement in comparison to animals of a non-treated control group of the same species in a vaccine efficacy parameter selected from the group consisting of a reduction in the loss of weight gain, a shorter duration of viremia, a reduction in viral excretion, a lower virus load, and any combination thereof.
24. The method according to claim 21 , wherein the anti-PCV2 antibodies are present in an antibody titer of at least 1:100-1:320 as determined in a PCV-specific indirect immunofluorescence assay.
25. The method according to claim 24 , wherein the treated animals have said anti-PCV2 antibody titre at the time the PCV2 antigen is administered.
26. The method of claim 21 , wherein the immunogenic composition further comprises a veterinary-acceptable carrier.
27. The method of claim 26 , wherein the veterinary-acceptable carrier is an adjuvant.
28. The method of claim 21 , wherein the immune response against PCV2 results in increased PCV2 serological titers two months after administration compared to a non-treated control group.
29. The method of claim 21 , wherein the immune response to PCV2 is a protective immunological response.
30. The method according to claim 21 , wherein the treatment results in a reduction in lymphoid infection by PCV2 as determined by immunohistochemistry.
31. A method for the treatment of
c) PCV2 infection; or
d) clinical symptoms caused by or associated with a PCV2 infection in piglets having anti-PCV2 antibodies, comprising the step of administering a single dose of an immunogenic composition comprising a PCV2 ORF2 antigen and gentamicin and/or merthiolate to a piglet, wherein the single dose is effective for the vaccination of a piglet 3 weeks of age or older against PCV2 infection.
32. The method according to claim 31 , wherein said anti-PCV2 antibodies are maternal antibodies.
33. The method according to claim 31 , wherein said treatment of PCV2 infection results in an improvement in comparison to animals of a non-treated control group of the same species in a vaccine efficacy parameter selected from the group consisting of a reduction in the loss of weight gain, a shorter duration of viremia, a reduction in viral excretion, a lower virus load, and any combination thereof.
34. The method according to claim 31 , wherein the anti-PCV2 antibodies are present in an antibody titer of at least 1:100-1:320 as determined in a PCV-specific indirect immunofluorescence assay.
35. The method according to claim 34 , wherein the treated animals have said anti-PCV2 antibody titre at the time the PCV2 antigen is administered.
36. The method according to claim 34 , wherein the immunogenic composition further comprises a veterinary-acceptable carrier.
37. The method of claim 36 , wherein the veterinary-acceptable carrier is an adjuvant.
38. The method of claim 31 , wherein the vaccination results in an immune response against PCV2 that includes increased PCV2 serological titers two months after administration compared to a non-treated control group.
39. The method of claim 38 , wherein the immune response to PCV2 is a protective immunological response.
40. The method according to claim 31 , wherein the treatment results in a reduction in lymphoid infection by PCV2 as determined by immunohistochemistry.
41. A method for the vaccination of piglets 3 weeks of age or older against PCV2 infection comprising the step of administering a single dose of an immunogenic composition comprising a PCV2 ORF2 antigen and a veterinary-acceptable carrier to a piglet, wherein the piglet has anti-PCV2 antibodies, and wherein the single dose induces an immune response against PCV2 in the piglet.
42. The method according to claim 41 , wherein said anti-PCV2 antibodies are maternal antibodies.
43. The method according to claim 41 , wherein said vaccination against PCV2 infection results in an improvement in comparison to piglets of a non-treated control group of piglets in a vaccine efficacy parameter selected from the group consisting of a reduction in the loss of weight gain, a shorter duration of viremia, a reduction in viral excretion, a lower virus load, and any combination thereof.
44. The method according to claim 41 , wherein the anti-PCV2 antibodies are present in an antibody titer of at least 1:100-1:320 as determined in a PCV-specific indirect immunofluorescence assay.
45. The method according to claim 44 , wherein vaccinated piglets have said anti-PCV2 antibody titre at the time the PCV2 antigen is administered.
46. The method of claim 41 , wherein the immunogenic composition further comprises gentamicin and/or merthiolate.
47. The method of claim 41 , wherein the veterinary-acceptable carrier is an adjuvant.
48. The method of claim 41 , wherein the immune response against PCV2 results in increased PCV2 serological titers two months after administration compared to a non-treated control group.
49. The method of claim 41 , wherein the immune response to PCV2 is a protective immunological response.
50. The method according to claim 41 , wherein the vaccination results in a reduction in lymphoid infection by PCV2 as determined by immunohistochemistry.